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ABSTRACT
MicroRNAs (miRNAs) play an important role in
diverse physiological processes and are potential
therapeutic agents. Synthetic oligonucleotides
(ONs) of different chemistries have proven success-
ful for blocking miRNA expression. However, their
specificity and efficiency have not been fully
evaluated. Here, we show that peptide nucleic
acids (PNAs) efficiently block a key inducible
miRNA expressed in the haematopoietic system,
miR-155, in cultured B cells as well as in mice.
Remarkably, miR-155 inhibition by PNA in primary
B cells was achieved in the absence of any trans-
fection agent. In mice, the high efficiency of the
treatment was demonstrated by a strong overlap
in global gene expression between B cells isolated
from anti-miR-155 PNA-treated and miR-155-
deficient mice. Interestingly, PNA also induced add-
itional changes in gene expression. Our analysis
provides a useful platform to aid the design of effi-
cient and specific anti-miRNA ONs for in vivo use.
INTRODUCTION
The discovery of small regulatory RNAs such as
microRNAs (miRNAs) has added a new layer of control
to the mechanisms directing gene expression. To date, the
number of known human miRNA loci is 721 (1). At least
30% of protein-coding genes are estimated to be regulated
by miRNAs, establishing them as one of the largest classes
of regulatory molecules. By binding to complementary
regions on their target mRNAs, they mediate gene
silencing by translational repression, mRNA degradation
or both (2). MiRNAs regulate a wide variety of biological
processes such as proliferation, diﬀerentiation, cellular mi-
gration, cell fate determination and apoptosis. Not sur-
prisingly, deregulation of miRNA expression has been
linked to human diseases such as cancer and autoimmune
dysfunction. One of the ﬁrst miRNAs identiﬁed with
oncogenic potential was miR-155. Encoded within an
exon of the non-coding RNA BIC, miR-155 is deregulated
in a number of diﬀerent human cancers, most of which are
of B-cell origin (3–6). Moreover, miR-155 over-expression
during B-cell development is suﬃcient to trigger B-cell
transformation (7). High levels of miR-155 are not
restricted to transformed cells. In the course of an
immune response, lymphoid cells up-regulate miR-155
(8,9). Induction of miR-155 profoundly aﬀects gene
expression in T and B cells, resulting in reduced expression
of dozens of target genes (8,10).
The emergence of miRNAs as regulators of malignant
transformation or autoimmunity is likely to have an
impact on gene therapies designed to block tumour pro-
gression or inﬂammation. Further, the potential for
miRNA antagonists as therapeutic agents in vivo has
been illustrated for miR-122 (11,12), a liver-speciﬁc
miRNA that has direct control over cholesterol biosynthe-
sis and which is required for hepatitis C infection (13). An
LNA/DNA anti-miR-122 oligonucleotide (ON) has been
shown to be eﬀective in suppressing hepatitis C viremia
and is currently in phase I clinical trials (14).
A central goal in eﬀorts to deﬁne miRNA antagonists
with potential use in the clinic is the ability to synthesize
stable and speciﬁc miRNA antagonists on a scale suitable
for in vivo studies. Peptide nucleic acid (PNA; Figure 1a) is
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an uncharged ON analogue in which the sugar–phospho-
diester backbone of DNA/RNA has been replaced by an
achiral structure consisting of N-(2-aminoethyl)-glycine
units. PNA ONs show high aﬃnity and sequence speciﬁ-
city for complementary RNA and DNA, and also bear
high chemical and metabolic stability (15). PNA has
been exploited as an antisense agent for various applica-
tions in diagnostics and as potential therapeutics, often
with attached peptides (16). PNA has also been shown
to possess antisense biological activities in vivo with little
or no toxicity (17–20). We showed previously that a
23-mer PNA, containing just four lys residues, was able
to inhibit miR-122 in human liver cells and primary rat
hepatocytes in culture without need for a transfection
agent or attachment of a cell-penetrating peptide (21).
However, PNAs have not been used hitherto for inhibiting
miRNAs in vivo. Indeed, the widespread usage of PNA
in vivo has been limited by the unavailability of an auto-
mated laboratory synthesis method that allows eﬃcient
synthesis of PNA oligomers of suﬃcient length and in
suﬃcient quantities for in vivo studies from commercially
available monomers.
In this article, we describe an automated microwave-
assisted method for medium-scale (50 mmol) synthesis of
PNA, using commercially available Fmoc/Bhoc PNA
monomers and a CEM Liberty microwave peptide synthe-
sizer, which results in rapid assembly and synthesis of
high-purity PNA in good yields. We then illustrate the
usefulness of PNA for miRNA inhibition by showing its
ability to inhibit miR-155 expression and function in
primary murine B cells both in culture and in vivo. By
comparing the gene expression proﬁles of B cells isolated
from the spleens of mice treated with anti-miR-155 PNA,
untreated B cells and miR-155-deﬁcient B cells, we ﬁnd
that PNA-treated mice showed alterations in gene expres-
sion similar to those from miR-155-deﬁcient mice, thus
validating anti-miR PNA targeting in vivo. In addition,
numerous additional genes are also altered in expression
levels upon in vivo PNA treatment.
MATERIALS AND METHODS
Synthesis of K-PNA-K3 ONs
The microwave-assisted method for PNA assembly was
developed using a commercial microwave peptide synthe-
sizer (Liberty, CEM Corporation) and carried out using
commercially available Fmoc/Bhoc (9-ﬂuorenylmet
hoxycarbonyl/benzhydryloxycarbonyl) PNA monomers
(Link Technologies, Scotland). PNA oligomers containing
a C-terminal amide were synthesized with Rink-Amide
ChemMatrix (Matrix Innovation) solid support, and
PyBOP (benzotriazol-1-yltris-pyrrolidinophosphonium
hexaﬂuorophosphate) as coupling agent. Detailed
methods of synthesis are supplied in Supplementary
Material. PNA ONs are 23-mer sequence a, Cys-K-50-A
CAAACACCATTGTCACACTCCA-30-KKK (21);
Figure 1. (a) Schematic representation of a PNA monomer unit. (b) Schematic representation of the cycle of microwave-assisted PNA synthesis on
solid support. Fmoc/Bhoc are orthologous protecting groups for primary and nucleobase amino groups, respectively. The applied microwave pulse is
indicated by a ﬁlled star symbol. The empty star represents an applied microwave pulse when the growing chain consists of natural amino acids only,
or no microwave if the synthesized chain contains at least one PNA monomer. Activator: PyBOP; base: DIPEA for amino acids or DIPEA/Lutidine
for PNA; ﬁnal cleavage/deprotection: TFA/TIS/H2O 95:2.5:2.5. (c) Typical MALDI-TOF mass spectra of crude 23-mer PNA (sequence a)
synthesized by standard automated non-microwave method on a PAL-PEG-PS solid support (left panel) or by microwave-assisted synthesis on a
PAL-PEG-PS support (sequence a, centre panel) or on a ChemMatrix solid support (sequence b, right panel).
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23-mer anti-miR-155K-PNA-K3 (sequence b), K-5
0-ACC
CCTATCACAATTAGCATTAA-30-KKK; 23-mer
scrambled-anti-miR-155K-PNA-K3, K-5
0-ACCCAATC
GTCAAATTCCATATA-30-KKK; 18-mer non-targeting
K-PNA-K3-1, dK-5
0-CACCATTGTCACACTCCA-30-
dKdKdK; 18-mer non-targeting K-PNA-K3-2, Cys-
K-50-CACCATTGTCACACTCCA-30-KKK; and 18-mer
non-targeting K-PNA-K3-3, dK-5
0-ACCTCCAACTGCC
TATAC-30-dKdKdK. Sequences contained lys residues in
either all L or all D form, for cellular and in vivo studies,
respectively. PNA ONs were puriﬁed by reversed-phase
high-pressure liquid chromatography (RP-HPLC) using
a C18 Waters XBridge BEH130 10-mm column at 36C
in triﬂuoroacetic acid buﬀers (buﬀer A: 0.1%
triﬂuoroacetic acid (TFA) in water; buﬀer B: 90% aceto-
nitrile/10% water/0.1% TFA). Collected fractions were
analysed by matrix-assisted laser desorption/ionization-
time of ﬂight mass spectrometry (MALDI-TOF) on a
Voyager DE Pro BioSpectrometry workstation by
mixing eluate:matrix in the ratio 1:1 (in microliters).
Matrix consisted of a-cyano-4-hydroxynnamic acid
(10mg/ml) in acetonitrile/3% TFA (1:1, vol/vol).
Fractions containing pure material were combined,
lyophilized and subsequently dissolved in water.
Oligomers were dissolved in de-ionized water and stored
at 80C after ﬁltering through a 0.22- mm cellulose
acetate membrane.
Primary B-cell puriﬁcation, cell transfections and RNA
extractions
Splenic primary B cells were puriﬁed from adult C57BL/6J
mice or miR-155-deﬁcient mice backcrossed six times to
C57BL/6J background (8). For cell culture, splenocytes
were T-cell depleted using Thy1.2 and complement. Cells
were subsequently stimulated using 10–20 mg/ml lipopoly-
saccharide (LPS; Sigma) and 25 ng/ml IL-4.
Electroporation of primary B cells with K-PNA-K3 ONs
was carried out with an Amaxa system (Lonza) using the
corresponding mouse nucleofector buﬀer solution and fol-
lowing manufacturer’s instructions. After electroporation,
cells were cultured in the presence of LPS and IL-4 for
24–48 h before RNA extraction and analysis. RNA was
extracted with Trizol following manufacturer’s instruc-
tions. For free-delivery experiments, K-PNA-K3 ONs
were incubated for 4–8 h with 2 106 B cells, previously
activated with LPS and IL-4 for 12–16 h, in 500-ml
PNA-transfection buﬀer (Optimem; 20 mg/ml LPS;
25 ng/ml IL-4). Subsequently, cells were cultured in
FCS-containing media in the presence of LPS and IL-4.
RNAs were puriﬁed and analysed as described earlier.
In vivo experiments
All mice used in this study were maintained in a 12-h light/
dark cycle, and experiments were conducted according to
the Home Oﬃce guidelines. ONs were dissolved in saline
and administered to mice based on body weight in the
indicated doses by the intraperitoneal route. At study ter-
mination, mice were sacriﬁced and tissues were collected
for further analysis.
Polyacrylamide gel electrophoresis and northern blots
Polyacrylamide gel electrophoresis (PAGE) and northern
blots were carried out as described previously (21). RNA
band size was estimated by running a 32P-labelled RNA
ladder (Decade-Markers, Applied Biosystems), following
manufacturer’s instructions.
Real-time reverse-transcription PCR (qRT-PCR)
Messenger RNAs of selected genes were quantiﬁed relative
to the indicated house-keeping genes using a 7900 HT Fast
Real-Time PCR System (Applied Biosystems) and a
one-step RT–PCR approach (QuantiTect Probe
RT–PCR, Qiagen) (21).
Microarray hybridization and analysis
For microarray experiments, splenic B cells were puriﬁed
by positive selection using MACS B220-microbeads ac-
cording to the manufacturer’s instructions (Miltenyi)
and purity was >95%. Following extraction of RNA
using Trizol, integrity was assessed by capillary electro-
phoresis using a BioAnalyser 2100 (Agilent
Technologies), and its concentration was determined
using a NanoDrop ND-1000 spectrophotometer.
Aliquots of total RNA (200 ng) were then labelled using
Aﬀymetrix’s WT Sense Target labelling kit, and
hybridized to Mouse Gene 1.0 ST arrays (Aﬀymetrix) fol-
lowing the manufacturer’s instructions. After washing,
arrays were scanned using a GS 3000 scanner
(Aﬀymetrix).
Microarray CEL ﬁles were processed and normalized
with Aﬀymetrix Power Tools (APTs), using the
RMA-sketch method and obtaining summarized expres-
sion values for each transcript. Quality checks and all
further analysis were carried out in Bioconductor (22).
Probe-sets, not from the ‘main’ category and those with
cross-hybridization potential, were removed according to
the Aﬀymetrix NetAﬀx release 29 annotation. In order to
assess diﬀerential expression, limma was used to ﬁt linear
models, using an empirical Bayes approach to shrink the
estimated variance (23). After this step, non-speciﬁc ﬁlter-
ing was carried out, by calculation of the interquartile
range and by excluding 50% of the probe-sets with
lowest variability. Diﬀerentially expressed genes were
then selected that passed a fold-change cut-oﬀ of 1.2
with a false discovery rate (FDR) of 10%, as estimated
using the Benjamini–Hochberg method (24). These criteria
were selected to highlight the diﬀerences and similarities
between diﬀerentially expressed genes in PNA-treated and
miR-155-knockout samples. All microarray data has been
deposited in the ArrayExpress database (accession
number: E-MEXP-2587).
RESULTS
Eﬃcient synthesis of PNAs using a microwave-assisted
method
PNA oligomers (Figure 1a) have been synthesized previ-
ously on solid support using Boc/benzyl chemistry (15) by
Fmoc/DDE chemistry (25) and by a novel PNA synthesis
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method using a benzothiazole-2-sulfonyl group as
amino-protecting group (26). More commonly Fmoc/
Bhoc chemistry is now used, because such protected
PNA monomers are commercially available (27–31).
Synthesis of a 23-mer anti-miR PNA using a conventional
peptide synthesizer was reported earlier (21,31). At this
length, we found that isolated yields of PNA were quite
low (just a few percent). Further, there was a need for
double-coupling reactions of 30min each (31), because
the eﬃciency of PNA-coupling reactions was poor.
The synthesis of peptides and peptidomimetics has been
revolutionized using microwave-assisted solid-phase
coupling methods that rely on the application of a micro-
wave pulse to drive coupling and deprotection reactions to
completion. Microwave assistance is particularly valuable
for diﬃcult peptide couplings to reduce chain aggregation
and to improve coupling eﬃciencies (32–34). A method
has been described recently for the orthogonal synthesis
of a short PNA peptide using DDE/Mmt-protected PNA
monomers (35), but such monomers are not commercially
available. Here, we present the implementation of
microwave-assisted synthesis of PNA using a commercial
microwave peptide synthesizer (Liberty, CEM
Corporation) and carried out using commercially avail-
able Fmoc/Bhoc PNA monomers.
A cycle of PNA synthesis is analogous to that of
standard Fmoc solid-phase peptide synthesis and
consists of PNA monomer coupling, capping of unreacted
amino groups and terminal Fmoc deprotection
(Figure 1b). A microwave pulse is applied in all amino
acid- or PNA-coupling steps. For PNA residues, a single
coupling of 30min duration is suﬃcient for optimal
oligomer assembly. Microwave energy is also applied
during Fmoc-deprotection steps, but only for those
involving amino acids when no PNA is present on the
support. Microwave pulsing was not used for
Fmoc-deprotection reactions of terminal PNA residues
or for amino acids when PNA was present on the
support, as side reactions on the PNA were observed
(36). In all cases, power, temperature and duration of
the microwave pulse were adjusted depending on the par-
ticular step (Supplementary Data). Compared with our
previously reported method for PNA synthesis carried
out at room temperature on a conventional robotic syn-
thesizer (21,31), the assembly of a 23-mer PNA oligomer
(including 4 lys residues) by the microwave-assisted
method is overall 2.5-fold faster and was completed
within 24 h.
With the conventional synthesis method on a synthesis
scale of 5–10mmol with the PAL-PEG-PS solid support
(31), the MALDI-TOF mass spectrum of the crude syn-
thesis product, before puriﬁcation of a 23-mer PNA plus 5
amino acids (sequence a, Cys-K-PNA-K3), showed only a
low yield of the desired product (Figure 1c, left panel, and
data not shown). In contrast, the mass spectrum of the
same Cys-K-PNA-K3 23-mer PNA synthesized using the
microwave-assisted method and the same PAL-PEG-PS
support showed a clearly improved amount of 23-mer
product (sequence a, Figure 1c, middle panel). The
overall isolated yield after HPLC puriﬁcation was 5%
(Table 1). We then investigated the alternative
ChemMatrix solid support for the synthesis of a 23-mer
containing four lys residues (K-PNA-K3, sequence b,
anti-miR-155), and the mass spectrum of the crude syn-
thesis product showed a further improved result
(Figure 1c, right panel). The overall isolated yield after
HPLC was 10% (Table 1). Shorter 18-mer oligomers
were also synthesized with ﬁnal overall isolated yields of
15% in the case of the PAL-PEG-PS support and 20%
in the case of the ChemMatrix support (Table 1). The
yields obtained provide milligram quantities of PNA suf-
ﬁcient for mouse studies.
PNA ONs inhibit miR-155 expression in cultured B cells
We focused our analysis of inhibition of miR-155 on B
cells due to the functional relevance of miR-155 in this cell
type and previous identiﬁcation of target genes (8–10). It is
known that bacterial LPS triggers miR-155 expression in
cultured B cells (9,10), and therefore we ﬁrst determined
the kinetics of miR-155 expression by incubation of mouse
Table 1. Examples of PNA ONs synthesized by microwave-assisted solid-phase synthesis
Peptide sequence Length Solid support Yield (%) Name
Cys-K-50-ACAAACACCATTGTCACACTCCA-30-KKK 23+5aa PAL-PEG-PS 5.0 Cys-K-PNA-K3
23-mer
(sequence a)
dK-50-CACCATTGTCACACTCCA-30-dKdKdK 18+4aa PAL-PEG-PS 15.7 dK-PNA-dK3-1
18-mer
Cys-K-50-CACCATTGTCACACTCCA-30-KKK 18+5aa PAL-PEG-PS 14.9 Cys-K-PNA-K3-2
18-mer
dK-50-ACCCCTATCACAATTAGCATTAA-30-dKdKdK 23+4aa ChemMatrix 10.4 Cys-K-PNA-K3
23-mer
(sequence b)
dK-50-CACCATTGTCACACTCCA-30-dKdKdK 18+4aa ChemMatrix 22.3 dK-PNA-dK3-1
18-mer
dK-50-ACCTCCAACTGCCTATAC-30-dKdKdK 18+4aa ChemMatrix 19.8 dK-PNA-dK3-3
18-mer
PNA ONs contained an N-terminal Cys for post-synthetic modiﬁcation and four lys residues for improved solubility and cell uptake. Yield refers
to the percentage of product after HPLC puriﬁcation relative to the amount of starting solid support. Sequences a and b refer to ONs shown in
Figure 1c.
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primary B cells with LPS (Supplementary Figure S1).
miR-155 expression was induced very rapidly and
reached a plateau at 24-h post-initiation of treatment,
which was sustained for at least 3 days, in agreement
with previous data (10,37). Thus, we tested the activity
of a 23-mer anti-miR-155K-PNA-K3 ON by electropor-
ation into LPS-activated primary B cells (Figure 2).
Northern blot analysis showed the expected dose–
response on miR-155 inhibition, with a 60% knockdown
of miR-155 with 4-mg PNA.
The K-PNA-K3 was evaluated further for its ability to
be internalized by primary B cells and to block miR-155
expression in the absence of any additional transfection
agent or other internalization procedure, as previously
obtained for miR-122 inhibition in hepatocytes (21).
Primary B cells were incubated with diﬀerent concentra-
tions of anti-miR-155K-PNA-K3 or its scrambled
sequence, scr-anti-miR-155, in the presence of LPS.
Figure 3a shows that anti-miR-155K-PNA-K3 was eﬃ-
ciently internalized by activated primary B cells unaided
and substantially reduced the levels of endogenous
miR-155 at concentrations of 1–10 mM. The miRNA
inhibition eﬀect was sequence speciﬁc, as the scrambled
control (scr-anti-miR-155) did not show this ability. As
expected, in B cells obtained from miR-155-deﬁcient
mice (miR-155/), miR-155 expression was not
detected, while B cells from heterozygous mice for
miR-155 contained intermediate levels of the miRNA
(Figure 3a).
To evaluate further the functional activity of anti-miR
PNA ONs, we measured the extent of de-repression of
endogenous targets of miR-155. It has been shown previ-
ously that in activated B cells, miR-155 regulates the
abundance of numerous mRNAs, including Bat5, Jarid2
and Sfpi1 (10). Cells treated with the anti-miR-
155K-PNA-K3 ON at 10 mM showed a strong 3- to
4-fold de-repression of these target genes (Figure 3b), par-
tially mimicking the eﬀect of deletion of miR-155/.
Interestingly, deletion of only one miR-155 allele
(miR-155+/) caused strong target de-repression,
indicating a miR-155 gene dosage eﬀect. The lack of
activity seen for the scrambled control ON by northern
blot is corroborated by the lack of a measurable eﬀect on
miR-155-regulated genes in cells incubated with this ON.
Eﬃcient inhibition of miR-155 in vivo by a PNA anti-miR
Next, we examined the ability of anti-miR-155
dK-PNA-dK3 ON (sequence b, Table 1, line 4; D-lys
residues were used to ensure proteolytic stability) to
block miR-155 expression in vivo. Because naı¨ve cells
express low amounts of miR-155, we examined whether
LPS could promote acute induction of miR-155 in
splenocytes, as is known to occur in bone marrow cells
(38). We found that intraperitoneal injection of 100 mg of
LPS was the optimal sub-lethal dose for inducing miR-155
expression in the spleen. Moreover, miR-155 expression
peaked at 24-h post-administration and returned to
steady state levels by 72 h (Supplementary Figure S2).
Figure 3. miR-155 inhibition in LPS-activated primary B cells with K-PNA-K3 ONs by free delivery. (a) Northern blot of total RNA from
LPS-activated B cells treated with the corresponding K-PNA-K3 ON in media without antibiotics for 4–6 h, washed and further incubated for
18–20 h in full media. RNA from miR-155+/ and miR-155/ B cells were included as controls. Each lane corresponds to an individual experi-
mental replicate. (b) qRT-PCR of miR-155 validated target genes, Bat5, Jarid2 and Sfpi1 (Pu.1) in miR-155+/, miR-155/ or wild-type primary B
cells, incubated with 10-mM anti-miR-155 PNA. B2m expression was used as endogenous control. Primary B-cell cultures were pre-activated with
LPS overnight before incubation with PNA.
Figure 2. A total of 2 106 primary B cells were electroporated with
the indicated amounts of anti-miR-155 PNA or control anti-miR-155
LNA/DNA (Exiqon). RNA was extracted and analysed by northern
blot 24 h post-transfection. Cells were cultivated with LPS supple-
mented media overnight prior to PNA transfection. The
indicated masses correspond to 1.47, 2.94 and 5.88mM PNA, or
1.39mM LNA ON.
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Based on these observations, mice were dosed systemically
at 50mg PNA/kg/day for 2 days and analysed 24 h after
the last injection (at which time miR-155 expression is
maximal). As shown in Figure 4a, RNA isolated from
the spleens of LPS-treated mice showed a strong induc-
tion of miR-155, which was completely abolished by
administration of the anti-miR-155 PNA. The eﬀect
appeared to be sequence speciﬁc as evidenced by the
lack of activity of the control scrambled PNA sequence,
and the unaltered levels of the unrelated miRNA, miR-16.
Because miR-155 is up-regulated in splenic B cells
upon LPS treatment, northern blot analysis showed
that the observed miR-155 inhibition by anti-miR-
155K-PNA-K3 was also seen in this splenic B-cell popu-
lation (Figure 4b and c).
Genome-wide analysis of gene expression shows
enrichment of miR-155-binding sites in mRNAs
up-regulated in B cells from mice deﬁcient in
miR-155/ or treated with anti-miR-155
To evaluate the eﬃcacy and speciﬁcity of the PNA treat-
ment in mice, we compared gene expression proﬁles
of splenic B cells from either LPS administered
miR-155-deﬁcient animals receiving vehicle control
(phosphate buﬀered saline, PBS), or LPS administered
wild-type animals receiving either PBS or anti-miR-155
dK-PNA-dK3 with the dosing regimen shown in Figure
4a.
In all, 474 transcripts were signiﬁcantly up-regulated
and 344 were down-regulated in miR-155-deﬁcient B
cells relative to their wild-type counterparts (diﬀerential
expression more than 1.2-fold and 10% FDR). Among
the deregulated genes are transcription factors, adhesion
molecules, chemotaxis regulators and signalling mol-
ecules. In support with our previous observation that
anti-miR-155 PNA eﬃciently blocks miR-155 both in
cell culture and in vivo, the ON treatment induced
changes in mouse B-cell gene expression that recapitulated
deﬁciency of miR-155 (Figure 5a). In particular, 76% of
the up-regulated and 80% of the down-regulated genes in
the miR-155-deﬁcient samples passed the same
fold-change and FDR cut-oﬀs in the PNA-treated
samples (Figure 5b and Supplementary Table S1).
However, when all diﬀerentially expressed genes are con-
sidered, a substantially higher number of genes are found
in the PNA-treated versus miR-155/ group, as shown by
the Venn diagram in Figure 5b. Gene ontology analysis
revealed enrichment in pathways related to protein catab-
olism and general cellular metabolism (data not shown).
We next focused our analysis on predicted miR-155
mRNA targets. This was based on computational and
experimental results indicating that miRNA targets
contain a perfect Watson–Crick matching sequence of
6–8 nt between the 50-end of an miRNA (referred to as
the ‘seed’ region) and the 30-unstranslated region (30-
UTR) of the mRNAs (39). Moreover, we have previously
shown how the enrichment in 30-UTR sequences comple-
mentary to the miR-155 seed region reﬂects direct target-
ing by this miRNA (8,10,40). As expected, miR-155 seed
matches are statistically over-represented in the 30-UTR
sequences of the transcripts up-regulated in
miR-155-deﬁcient B cells (Figure 5c). This eﬀect is
observed both for transcripts consistently up-regulated
(‘intersect’) as well as those exclusively up-regulated in
the miR-155 knockout. The 724 transcripts that were
only up-regulated in the PNA samples and all the
down-regulated groups showed no seed complement en-
richment (Figure 5c). We also found that several experi-
mentally validated mRNA targets of miRNA-155 were
up-regulated in both miR-155/ and PNA-treated
groups (Supplementary Table S1): Inpp5d (also known
as Ship1) (41), Agtrap (42), Arid2 and Zfp652 (43).
Figure 4. In vivo miR-155 inhibition with dK-PNA-dK3 ONs. (a) Schematic representation of a dosage regimen and northern blot analysis of total
RNA (whole spleen, Day 3) from animals treated with the indicated dK-PNA-dK3 anti-miR. Each lane represents an individual mouse sample.
RNAs from miR-155/ or wild-type mice with no LPS administration were included as controls. (b) miR-155 levels in splenic B cells puriﬁed from
mice receiving either LPS (i.p., 100mg) or vehicle control (PBS). Measurement by qRT-PCR using RNU6-2 RNA as endogenous control. Error bars
indicate the standard deviation between experimental replicates (duplicates). (c) Ten micrograms of RNA from isolated splenic B cells from the
indicated mice group were subjected to northern blot analysis for miR-155, miR-16 and RNU6-1 detection. Each lane corresponds to an individual
mouse sample.
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Several other up-regulated mRNAs, not all containing
miR-155 seed sequences, were identiﬁed in miR-155/
and PNA-treated groups that had already been found in
our previous microarray studies of miR-155-deﬁcient B
and T cells activated in culture: Sgk3, Mt1, Cxcl10 (10),
Ccl5, Map3k7ip1 and Il7r (8). These results demonstrate
that PNA inhibition of miR-155 in vivo recapitulates to a
great extent the eﬀect of genetic deletion of miR-155.
Additional changes in gene expression may have resulted
from cascade eﬀects of genes up-regulated by miR-155.
For example, the transcription factor c/ebp was shown
by LNA/DNA anti-miR treatment to be a target of
miR-155, and its up-regulation caused subsequent
down-regulation of G-CSF in myeloid cells (44).
In addition, we found novel targets up-regulated in
both, miR-155/ and PNA-treated groups, which con-
tained one or more miR-155 seed sequences, for
example: Tifa (TRAF-interacting protein with forkhead-
associated domain), Pik3ip1 (phosphoinositide-3-kinase
interacting protein 1), Map3k14 (mitogen-activated
Figure 5. Aﬀymetrix gene expression proﬁling of B cells from wild-type mice treated with PBS and of mice treated with dK-PNA-dK3 (3  50mg/
kg) and of B cells from miR-155/ mice. (a) Heat-map proﬁle showing relative expression across all samples of the diﬀerentially expressed
transcripts between miR-155/ and wild-type B cells from mice spleens. (b) Venn diagrams showing the overlap of diﬀerentially expressed genes
in PNA-treated and miR-155/ groups, relative to wild-type B cells. (c) Seed-enrichment analysis for the groups indicated in the Venn diagram,
considering only genes with an annotated 30-UTR sequence. In all cases, gene lists were selected with a fold-change >1.2 and FDR <10%.
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protein kinase kinase kinase 14), Il6ra (interleukin 6
receptor a) and Apobec1 (apolipoprotein B mRNA
editing enzyme, catalytic polypeptide 1).
As suggested by the seed enrichment analysis
(Figure 5c), it is likely that up-regulation of the 724 tran-
scripts found only in the PNA-treated group is not due
to direct miR-155 inhibition, instead due to a combin-
ation of other indirect eﬀects of in vivo PNA anti-miR
treatment, including oﬀ-target eﬀects and PNA
chemistry-speciﬁc eﬀects. Enrichment was observed
neither in the 30-UTRs of these transcripts for seed
matches of miR-155* (the passenger strand of the
mature miR-155) nor for sequences complementary
to the ﬁrst eight residues at the 50-end of the PNA (equiva-
lent to the seed sequence of an miRNA)
(Supplementary Figure S3). We also did not ﬁnd any pro-
pensity for complementary matching of the full-length
PNA to any regions in the whole transcripts (data not
shown).
DISCUSSION
The intrinsic role of miRNAs as regulators of gene expres-
sion, especially those miRNAs relevant to human diseases,
has opened up the possibility of modulating miRNA
expression for therapeutic purposes. ONs of diﬀerent
chemistries such as LNA/DNA mixmers, MOEs and
‘antagomirs’ have proven successful for blocking
miRNA expression in vivo, as exempliﬁed by targeting of
miR-122 and miR-155 (11,12,14,44,45). We have now
shown that PNA ONs are also eﬃcient in blocking
miRNA function in vivo. We chose to investigate PNA
ONs as inhibitors of miR-155, because we previously
characterized the function of this miRNA in primary B
cells (10). The in vivo studies reported here required the
production and puriﬁcation of milligram quantities of
PNA ONs, which was achieved using microwave-assisted
PNA assembly. This methodology allowed rapid synthesis
and a signiﬁcant increase in the quantity and quality of the
crude PNA product (Figure 1 and Table 1).
The eﬃcient unaided delivery of a 23-mer anti-miR-
155K-PNA-K3 in cultured primary B cells in the
presence of LPS is unprecedented (Figure 3a). Such cells
are generally known to be diﬃcult to transfect (46,47). By
measurement of the expression of miR-155 target genes
that we have previously identiﬁed in cultured B cells
(10), we were able to demonstrate a signiﬁcant eﬀect of
the PNA treatment on the regulation of miR-155 target
genes (Figure 3b). This ﬁnding strengthens the general
utility of PNA for miRNA targeting in primary cell
culture, as we had previously shown eﬃcient inhibition
of miR-122 in primary hepatocytes by a K-PNA-K3 (21).
When evaluated in vivo, anti-miR-155 dK-PNA-dK3 led
to a dramatic and sequence-speciﬁc decrease in
LPS-induced miR-155 levels in whole spleen or in the
puriﬁed splenic B-cell fraction (Figure 4). Hitherto, only
a few demonstrations of PNA eﬀectiveness in vivo have
been shown. Applications include PNA modiﬁed with a
peptide nuclear localization signal for splicing redirection,
PNA targeting of mRNAs or exon skipping (16,19,47–49).
We have, therefore, shown for the ﬁrst time that
lysine-bearing PNAs are also suitable for inhibiting
miRNAs in whole animals.
Experiments examining the ability of synthetic ONs to
block miRNA function have uncovered the potential of
such molecules for therapeutics. Our results extend these
studies showing the usefulness of PNAs for miRNA tar-
geting in animals and highlight the utility of comparing
the genetic and chemical approaches for the identiﬁcation
of speciﬁc and unspeciﬁc eﬀects. With this approach, we
have been able to show for the ﬁrst time the extensive
overlap in the expression proﬁles of B cells from
PNA-treated and miR-155/ mice (Figure 5a).
Interestingly, we found the expression levels of a signiﬁ-
cant number of other genes also aﬀected, including 724
genes up-regulated and 1138 genes that were
down-regulated only in the PNA-treated group
(Figure 5b). The mechanisms involved are not clear and
this will require a separate detailed study, but are likely
to derive from a combination of indirect eﬀects that
might include oﬀ-target eﬀects of the PNA and PNA
chemistry-speciﬁc eﬀects. Further gene expression studies
of this type will help to determine whether synthetic ONs
of diﬀerent backbone chemistry might confer particular
advantages over others in terms of reduced unrelated
gene expression alterations or a stronger direct
‘knockout’ recapitulation. It should be noted that we did
not observe any signs of toxicity in the mice treated with
PNA ONs (data not shown), in agreement with previous
results for PNA in vivo treatment (17,20), and a great deal
of detailed analysis will be needed to relate any particular
gene expression changes to particular unwanted side
eﬀects. However, such a genomics approach could
provide a useful platform as one criterion in the design
and assessment of ONs as blockers of RNA function and/
or as therapeutics.
B lymphocytes play an important role in immune re-
sponses against Gram-negative bacteria and their activa-
tion by LPS leads to enhanced antigen presentation,
proliferation and diﬀerentiation. Similar to myeloid cells,
systemic administration of LPS induced expression of
miR-155 in splenic B cells, which peaked at 24 h
(Supplementary Figure S2). The response to LPS by B
cells is the activation of the nuclear factor kappa B
(NF-KB) and mitogen-activated protein kinase (MAPK)
signalling pathways, and miR-155 itself seems to be at
least transiently under the control of NF-kB (9,48). Our
microarray analysis of up-regulated genes in
miR-155-deﬁcient or PNA-treated B cells in the presence
of LPS identiﬁed several genes that regulate these
pathways, for example, Map3k5/8/14 (mitogen-activated
protein 3-kinase 5, 8 and 14, respectively), Peli1 (Pellino 1;
only found in miR-155-deﬁcient cells) and Tifa.
Interestingly, Map3k8/14, Peli1 and Tifa are known acti-
vators of the NF-kB signalling pathway and both contain
at least one miRNA binding site in their 30-UTRs, sug-
gesting they may be direct miR-155 targets.
Among other up-regulated genes containing
miR-155-binding sites, we found Sgk3 (Serum/
Glucocorticoid Regulated Kinase 3), Pik3ip1
(Phosphoinositide-3-kinase Interacting Protein 1) and
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Inpp5d (Inositol polyphosphate-5-phosphatase D, Ship1),
all components of the PI3K pathway, a key modulator of
B-cell development and signalling (49). Inpp5d has already
been validated as a miR-155 target gene (41).
The contribution of all these genes to the regulation by
miR-155 of the B-cell response by LPS remains to be
understood, but it is likely to reﬂect deregulation of
multiple cellular processes, involving the induction of
both pro- and anti-inﬂammatory mediators. Thus, our
results have identiﬁed potential new targets under
miR-155 regulation in activated B cells in vivo, as well as
conﬁrmed previously known targets of miR-155. These
observations can guide future studies to unveil how the
network of miR-155-regulated genes contributes to the
LPS response in vivo.
Noteworthy also is the relationship between miR-155
and Inpp5d, which has interesting implications concerning
the possible therapeutic use of anti-miR-155 ONs. Diﬀuse
large B-cell lymphoma (DLBCL) has been characterized
with low levels of Inpp5d (50). Non-germinal
centre-DLBCL patients showed increased expression of
miR-155 and a concomitant decrease in Inpp5d levels,
which also correlated with poorer survival (50). It is, there-
fore, possible that therapies aimed at increasing Inpp5d
levels by reducing miR-155 expression could be beneﬁcial
in the treatment of speciﬁc types of lymphoma.
The combination of genetic approaches and synthetic
ON targeting miRNAs can be instrumental to dissect
in vivo responses. Improving the design of synthetic ONs
to block miRNA function to increase eﬃciency of
silencing but avoiding non-speciﬁc eﬀects will provide
new tools for uncovering the function of miRNAs and
better therapies for the treatment of human diseases.
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Supplementary Data are available at NAR Online.
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